<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRAVATAN Z - travoprost solution </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
These highlights do not include all the information needed to use <span class="Bold">TRAVATAN Z<span class="Sup">®</span></span> (travoprost ophthalmic solution) 0.004% safely and effectively.  See full prescribing information for <span class="Bold">TRAVATAN Z<span class="Sup">®</span></span>. <br><br><span class="Bold">TRAVATAN Z<span class="Sup">®</span> (travoprost ophthalmic solution) 0.004%</span><br><span class="Bold">Initial U.S. Approval:  2001</span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"><span class="Bold">TRAVATAN Z<span class="Sup">®</span></span> is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>. <span class="Underline"><a href="#splSectionPLRIndicationsUsage">(1)</a></span> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">One drop in the affected eye(s) once daily in the evening. <span class="Underline"><a href="#splSectionPLRDosageAdministration">(2)</a></span> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Solution containing 0.04 mg/mL travoprost ophthalmic solution. <span class="Underline"><a href="#splSectionPLRDosageFormsStrength">(3)</a></span> </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span>. </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span> of the iris, periorbital tissue (eyelid) and eyelashes can occur.  Iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> likely to be permanent. <span class="Underline"><a href="#splSection1">(5.1)</a></span> </p>
<p class="Highlighta">      </p>
<p class="Highlighta">Eyelash Changes. </p>
<p class="Highlighta">Gradual change to eyelashes including increased length, thickness and number of lashes.  Usually reversible. <span class="Underline"><a href="#splSection2">(5.2)</a></span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reaction (30% to 50%) is <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>. <span class="Underline"><a href="#splSection8">(6.1)</a></span> </p>
<p class="Highlighta"><span class="Bold">     </span> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> following long-term chronic use. <span class="Underline"><a href="#splSectionPLRPediatric">(8.4)</a></span> </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">
1	INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">
2	DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">
3	DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">
4	CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">
5	WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">
5.1   <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">
5.2   Eyelash Changes
</a></h2>
<h2><a href="#section-5.3" class="toc">
5.3   Intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">
5.4   <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span>
</a></h2>
<h2><a href="#section-5.5" class="toc">
5.5   Angle-closure, Inflammatory or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Neovascular Glaucoma</span>
</a></h2>
<h2><a href="#section-5.6" class="toc">
5.6   Bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span>
</a></h2>
<h2><a href="#section-5.7" class="toc">
5.7	Use with Contact Lenses
</a></h2>
<h1><a href="#section-6" class="toc">
6	ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">
6.1	Clinical Studies Experience
</a></h2>
<h1><a href="#section-7" class="toc">
8	USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">
8.1   Pregnancy
</a></h2>
<h2><a href="#section-7.2" class="toc">
8.3   Nursing Mothers
</a></h2>
<h2><a href="#section-7.3" class="toc">
8.4   Pediatric Use
</a></h2>
<h2><a href="#section-7.4" class="toc">
8.5   Geriatric Use
</a></h2>
<h2><a href="#section-7.5" class="toc">
8.6   Hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h1><a href="#section-8" class="toc">
11	DESCRIPTION
</a></h1>
<h1><a href="#section-9" class="toc">
12	CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-9.1" class="toc">
12.1   Mechanism of Action
</a></h2>
<h2><a href="#section-9.2" class="toc">
12.3   Pharmacokinetics
</a></h2>
<h1><a href="#section-10" class="toc">
13	NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">
13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-11" class="toc">
14	CLINICAL STUDIES
</a></h1>
<h1><a href="#section-12" class="toc">
16	HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-13" class="toc">
17	PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-13.1" class="toc">
17.1   Potential for <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span>
</a></h2>
<h2><a href="#section-13.2" class="toc">
17.2   Potential for Eyelash Changes
</a></h2>
<h2><a href="#section-13.3" class="toc">
17.3   Handling the Container
</a></h2>
<h2><a href="#section-13.4" class="toc">
17.4   When to Seek Physician Advice
</a></h2>
<h2><a href="#section-13.5" class="toc">
17.5  Use with Contact Lenses
</a></h2>
<h2><a href="#section-13.6" class="toc">
17.6  Use with Other Ophthalmic Drugs
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionPLRIndicationsUsage"></a><a name="section-1"></a><p></p>
<h1>
1	INDICATIONS AND USAGE
</h1>
<p class="First">TRAVATAN Z<span class="Sup">®</span> (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionPLRDosageAdministration"></a><a name="section-2"></a><p></p>
<h1>
2	DOSAGE AND ADMINISTRATION
</h1>
<p class="First">The recommended dosage is one drop in the affected eye(s) once daily in the evening.  TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> (travoprost ophthalmic solution) should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect. </p>
<p>Reduction of the intraocular pressure starts approximately 2 hours after the first administration with maximum effect reached after 12 hours.</p>
<p>TRAVATAN Z<span class="Sup">®</span> may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure.  If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. </p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="splSectionPLRDosageFormsStrength"></a><a name="section-3"></a><p></p>
<h1>
3	DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Ophthalmic solution containing travoprost 0.04 mg/mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionPLRContraindications"></a><a name="section-4"></a><p></p>
<h1>
4	CONTRAINDICATIONS
</h1>
<p class="First">None </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="splSectionPLRWarnings"></a><a name="section-5"></a><p></p>
<h1>
5	WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-5.1"></a><p></p>
<h2>
5.1   <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span>
</h2>
<p class="First">Travoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris, periorbital tissue (eyelid) and eyelashes. <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span> is expected to increase as long as travoprost is administered.  The <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of travoprost, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris is likely to be permanent, while <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>. The long term effects of increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> are not known.</p>
<p>Iris color change may not be noticeable for several months to years. Typically, the brown <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> (travoprost ophthalmic solution) 0.004% can be continued in patients who develop noticeably increased iris <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, these patients should be examined regularly. (see <span class="Underline"><a href="#splSection10">PATIENT COUNSELING INFORMATION, 17.1</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection2"></a><a name="section-5.2"></a><p></p>
<h2>
5.2   Eyelash Changes
</h2>
<p class="First">TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes.  Eyelash changes are usually reversible upon discontinuation of treatment. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection3"></a><a name="section-5.3"></a><p></p>
<h2>
5.3   Intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span>
</h2>
<p class="First">TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> should be used with caution in patients with active intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (e.g., <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>) because the <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may be exacerbated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection4"></a><a name="section-5.4"></a><p></p>
<h2>
5.4   <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span>, including <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span>, has been reported during treatment with travoprost ophthalmic solution.  TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection5"></a><a name="section-5.5"></a><p></p>
<h2>
5.5   Angle-closure, Inflammatory or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Neovascular Glaucoma</span>
</h2>
<p class="First">TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> has not been evaluated for the treatment of angle-closure, inflammatory or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">neovascular glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection6"></a><a name="section-5.6"></a><p></p>
<h2>
5.6   Bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span>
</h2>
<p class="First">There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of multiple-dose containers of topical ophthalmic products.  These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface (see <span class="Underline"><a href="#splSection12">PATIENT COUNSELING INFORMATION, 17.3</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection7"></a><a name="section-5.7"></a><p></p>
<h2>
5.7	Use with Contact Lenses
</h2>
<p class="First">Contact lenses should be removed prior to instillation of TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> and may be reinserted 15 minutes following its administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionPLRAdverseReactions"></a><a name="section-6"></a><p></p>
<h1>
6	ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection8"></a><a name="section-6.1"></a><p></p>
<h2>
6.1	Clinical Studies Experience
</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p>The most common adverse reaction observed in controlled clinical studies with TRAVATAN® (travoprost ophthalmic solution) 0.004% and TRAVATAN Z® (travoprost ophthalmic solution) 0.004% was <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span> which was reported in 30 to 50% of patients.  Up to 3% of patients discontinued therapy due to <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>. Ocular adverse reactions reported at an incidence of 5 to 10% in these clinical studies included decreased visual acuity, eye <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.  </p>
<p>Ocular adverse reactions reported at an incidence of 1 to 4% in clinical studies with TRAVATAN® or TRAVATAN Z® included <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4080997" conceptname="Corneal epithelial staining pattern">corneal staining</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, iris discoloration, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, lid margin crusting, ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">subconjunctival hemorrhage</span> and tearing.</p>
<p>Nonocular adverse reactions reported at an incidence of 1 to 5% in these clinical studies were <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>/<span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, prostate disorder, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span> and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="splSectionPLRPopulations"></a><a name="section-7"></a><p></p>
<h1>
8	USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPLRPregnancy"></a><a name="section-7.1"></a><p></p>
<h2>
8.1   Pregnancy
</h2>
<p class="First">Pregnancy Category C</p>
<p>Teratogenic effects: Travoprost was teratogenic in rats, at an intravenous (IV) dose up to 10 mcg/kg/day (250 times the maximal recommended human ocular dose (MRHOD), evidenced by an increase in the incidence of skeletal malformations as well as external and visceral malformations, such as fused sternebrae, domed head and <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span>.  Travoprost was not teratogenic in rats at IV doses up to 3 mcg/kg/day (75 times the MRHOD), or in mice at subcutaneous doses up to 1 mcg/kg/day (25 times the MRHOD).  Travoprost produced an increase in post-implantation losses and a decrease in fetal viability in rats at IV doses &gt; 3 mcg/kg/day (75 times the MRHOD) and in mice at subcutaneous doses &gt; 0.3 mcg/kg/day (7.5 times the MRHOD).</p>
<p>In the offspring of female rats that received travoprost subcutaneously from Day 7 of pregnancy to lactation Day 21 at doses of = 0.12 mcg/kg/day (3 times the MRHOD), the incidence of postnatal mortality was increased, and neonatal body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was decreased.  Neonatal development was also affected, evidenced by delayed eye opening, pinna detachment and preputial separation, and by decreased motor activity.</p>
<p>There are no adequate and well-controlled studies of TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> (travoprost ophthalmic solution) 0.004% administration in pregnant women.  Because animal reproductive studies are not always predictive of human response, TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPLRNursing"></a><a name="section-7.2"></a><p></p>
<h2>
8.3   Nursing Mothers
</h2>
<p class="First">A study in lactating rats demonstrated that radiolabeled travoprost and/or its metabolites were excreted in milk.  It is not known whether this drug or its metabolites are excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPLRPediatric"></a><a name="section-7.3"></a><p></p>
<h2>
8.4   Pediatric Use
</h2>
<p class="First">Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> following long-term chronic use.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPLRGeriatric"></a><a name="section-7.4"></a><p></p>
<h2>
8.5   Geriatric Use
</h2>
<p class="First">No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection9"></a><a name="section-7.5"></a><p></p>
<h2>
8.6   Hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Travoprost ophthalmic solution 0.004% has been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and also in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  No clinically relevant changes in hematology, blood chemistry, or urinalysis laboratory data were observed in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionPLRDescription"></a><a name="section-8"></a><p></p>
<h1>
11	DESCRIPTION
</h1>
<p class="First">Travoprost is a synthetic prostaglandin F analogue. Its chemical name is [1<span class="Italics">R</span>-[1α(<span class="Italics">Z</span>),2β(1<span class="Italics">E</span>,3<span class="Italics">R</span>*),3α,5α]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl) phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid, 1-methylethylester. It has a molecular formula of C<span class="Sub">26</span>H<span class="Sub">35</span>F<span class="Sub">3</span>O<span class="Sub">6</span> and a molecular weight of 500.55. The chemical structure of travoprost is:</p>
<div class="Figure"><img alt="
chemical
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=db08d5f3-6713-4372-a66c-fad3018ef5c6&amp;name=chemical.jpg"></div>
<p>Travoprost is a clear, colorless to slightly yellow oil that is very soluble in acetonitrile, methanol, octanol, and chloroform. It is practically insoluble in water.</p>
<p>TRAVATAN Z® (travoprost ophthalmic solution) 0.004% is supplied as sterile, buffered aqueous solution of travoprost with a pH of approximately 5.7 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 290 mOsmol/kg.</p>
<p>TRAVATAN Z® contains <span class="Bold">Active:</span> travoprost 0.04 mg/mL; <span class="Bold">Inactives:</span> polyoxyl 40 hydrogenated castor oil, <span class="Italics">sof</span>Zia® (boric acid, propylene glycol, sorbitol, zinc chloride), sodium hydroxide and/or hydrochloric acid (to adjust pH) and purified water, USP. Preserved in the bottle with an ionic buffered system, <span class="Italics">sof</span>Zia®.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionPLRClinicalPharm"></a><a name="section-9"></a><p></p>
<h1>
12	CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="splSectionPLRMechAction"></a><a name="section-9.1"></a><p></p>
<h2>
12.1   Mechanism of Action
</h2>
<p class="First">Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="splSectionPLRPharmacokinetics"></a><a name="section-9.2"></a><p></p>
<h2>
12.3   Pharmacokinetics
</h2>
<p class="First">Travoprost is absorbed through the cornea and is hydrolyzed to the active free acid. Data from four multiple dose pharmacokinetic studies (totaling 107 subjects) have shown that plasma concentrations of the free acid are below 0.01 ng/ml (the quantitation limit of the assay) in two-thirds of the subjects. In those individuals with quantifiable plasma concentrations (N=38), the mean plasma C<span class="Sub">max</span> was 0.018 ± 0.007 ng/ml (ranged 0.01 to 0.052 ng/mL) and was reached within 30 minutes. From these studies, travoprost is estimated to have a plasma half-life of 45 minutes. There was no difference in plasma concentrations between Days 1 and 7, indicating steady-state was reached early and that there was no significant accumulation.</p>
<p>Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the α(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond.</p>
<p>The elimination of travoprost free acid from plasma was rapid and levels were generally below the limit of quantification within one hour after dosing. The terminal elimination half-life of travoprost free acid was estimated from fourteen subjects and ranged from 17 minutes to 86 minutes with the mean half-life of 45 minutes. Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="splSectionPLRNonClinical"></a><a name="section-10"></a><p></p>
<h1>
13	NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPLRPrecautionsCarcinogen"></a><a name="section-10.1"></a><p></p>
<h2>
13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Two-year carcinogenicity studies in mice and rats at subcutaneous doses of 10, 30, or 100 mcg/kg/day did not show any evidence of carcinogenic potential. However, at 100 mcg/kg/day, male rats were only treated for 82 weeks, and the maximum tolerated dose (MTD) was not reached in the mouse study. The high dose (100  mcg/kg) corresponds to exposure levels over 400 times the human exposure at the maximum recommended human ocular dose (MRHOD) of 0.04 mcg/kg, based on plasma active drug levels.</p>
<p>Travoprost was not mutagenic in the Ames test, mouse micronucleus test or rat chromosome aberration assay. A slight increase in the mutant frequency was observed in one of two mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assays in the presence of rat S-9 activation enzymes.</p>
<p>Travoprost did not affect mating or fertility indices in male or female rats at subcutaneous doses up to 10 mcg/kg/day [250 times the maximum recommended human ocular dose of 0.04 mcg/kg/day on a mcg/kg basis (MRHOD)]. At 10 mcg/kg/day, the mean number of corpora lutea was reduced, and the post-implantation losses were increased. These effects were not observed at 3 mcg/kg/day (75 times the MRHOD).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="splSectionPLRClinicalStudies"></a><a name="section-11"></a><p></p>
<h1>
14	CLINICAL STUDIES
</h1>
<p class="First">In clinical studies, patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> and baseline pressure of 25-27 mmHg who were treated with TRAVATAN® (travoprost ophthalmic solution) 0.004% or TRAVATAN Z® (travoprost ophthalmic solution) 0.004% dosed once-daily in the evening demonstrated 7-8 mmHg reductions in intraocular pressure. In subgroup analyses of these studies, mean IOP reduction in black patients was up to 1.8 mmHg greater than in non-black patients. It is not known at this time whether this difference is attributed to race or to heavily pigmented irides.</p>
<p>In a multi-center, randomized, controlled trial, patients with mean baseline intraocular pressure of 24-26 mmHg on TIMOPTIC* 0.5% BID who were treated with TRAVATAN® (travoprost ophthalmic solution) 0.004% dosed QD adjunctively to TIMOPTIC* 0.5% BID demonstrated 6-7 mmHg reductions in intraocular pressure.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionPLRHowSupplied"></a><a name="section-12"></a><p></p>
<h1>
16	HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">TRAVATAN Z® (travoprost ophthalmic solution) 0.004% is a sterile, isotonic, buffered, preserved, aqueous solution of travoprost (0.04 mg/mL) supplied in Alcon's oval DROP-TAINER® package system.</p>
<p>TRAVATAN Z® is supplied as a 2.5 mL solution in a 4 mL and a 5 mL solution in a 7.5 mL natural polypropylene dispenser bottle with a natural polypropylene dropper tip and a turquoise polypropylene or high density polyethylene overcap. Tamper evidence is provided with a shrink band around the closure and neck area of the package.</p>
<p>2.5 mL fill           NDC 54868-5968-1<br></p>
<p>5 mL fill              NDC 54868-5968-0<br></p>
<p><span class="Bold">Storage:  </span>Store at 2° - 25°C (36° - 77°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPLRPatientInfo"></a><a name="section-13"></a><p></p>
<h1>
17	PATIENT COUNSELING INFORMATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection10"></a><a name="section-13.1"></a><p></p>
<h2>
17.1   Potential for <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span>
</h2>
<p class="First">Patients should be advised about the potential for increased brown <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the iris, which may be permanent. Patients should also be informed about the possibility of eyelid skin darkening, which may be reversible after discontinuation of TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span> (travoprost ophthalmic solution) 0.004%. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection11"></a><a name="section-13.2"></a><p></p>
<h2>
17.2   Potential for Eyelash Changes
</h2>
<p class="First">Patients should also be informed of the possibility of eyelash and vellus hair changes in the treated eye during treatment with TRAVATAN Z<span class="Bold"><span class="Sup">®</span></span>. These changes may result in a disparity between eyes in length, thickness, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, number of eyelashes or vellus hairs, and/or direction of eyelash growth.  Eyelash changes are usually reversible upon discontinuation of treatment. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection12"></a><a name="section-13.3"></a><p></p>
<h2>
17.3   Handling the Container
</h2>
<p class="First">Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection13"></a><a name="section-13.4"></a><p></p>
<h2>
17.4   When to Seek Physician Advice
</h2>
<p class="First">Patients should also be advised that if they develop an intercurrent ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), have ocular surgery, or develop any ocular reactions, particularly <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and eyelid reactions, they should immediately seek their physician's advice concerning the continued use of TRAVATAN Z<span class="Bold"><span class="Sup">®</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection14"></a><a name="section-13.5"></a><p></p>
<h2>
17.5  Use with Contact Lenses
</h2>
<p class="First">Contact lenses should be removed prior to instillation of TRAVATAN<span class="Bold"><span class="Sup">®</span></span> and may be reinserted 15 minutes following its administration.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection15"></a><a name="section-13.6"></a><p></p>
<h2>
17.6  Use with Other Ophthalmic Drugs
</h2>
<p class="First">If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.</p>
<p><span class="Bold">Rx Only</span></p>
<p>U.S. Patent Nos. 5,631,287; 5,889,052; 6,011,062; 6,235,781; 6,503,497 and 6,849,283</p>
<p>* TIMOPTIC is a registered trademark of Merck &amp; Co., Inc.</p>
<p>ALCON®</p>
<p>ALCON LABORATORIES, INC.</p>
<p>Fort Worth, Texas 76134 USA</p>
<p>© 2006, 2010 Alcon, Inc.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First"><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK       74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 54868-5968-1</p>
<p>Rx Only</p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=db08d5f3-6713-4372-a66c-fad3018ef5c6&amp;name=5968.jpg"></p>
<p>TRAVATAN Z<span class="Sup">®</span></p>
<p>(travoprost ophthalmic</p>
<p>solution) 0.004%</p>
<p>2.5 mL</p>
<p>STERILE</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRAVATAN Z 		
					</strong><br><span class="contentTableReg">travoprost solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5968(NDC:0065-0260)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRAVOPROST</strong> (TRAVOPROST) </td>
<td class="formItem">TRAVOPROST</td>
<td class="formItem">0.04 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYOXYL 40 CASTOR OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ZINC CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5968-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5968-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021994</td>
<td class="formItem">12/09/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bac29918-a4b8-4dbc-8620-986e9c6265cc</div>
<div>Set id: db08d5f3-6713-4372-a66c-fad3018ef5c6</div>
<div>Version: 1</div>
<div>Effective Time: 20110720</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
